A recent article from Bloomberg reports that Mylan has received preliminary notice that the FTC is investigating whether the company unfairly blocked EpiPen competitors from the marketplace. Did the company make minor changes to the product strictly for patent protection purposes? Enter agreements to stave off competition? Etc.? The company says no. We shall see.
Bottom Line. When we think about the PR problems that the pharmaceutical industry faces, we need to think more broadly than “price” in our actions and in our communications if we want to clean up our act in the eyes of the public.